New treatments for metastic prostate cancer

Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70.

Abstract

The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge - Dendreon) s the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana - Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).

MeSH terms

  • Cancer Vaccines / adverse effects
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Drug Interactions
  • Humans
  • Immunotherapy / methods
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / physiopathology
  • Prostatic Neoplasms / therapy*
  • Taxoids / adverse effects
  • Taxoids / pharmacology
  • Taxoids / therapeutic use*
  • Tissue Extracts / adverse effects
  • Tissue Extracts / immunology
  • Tissue Extracts / therapeutic use*

Substances

  • Cancer Vaccines
  • Taxoids
  • Tissue Extracts
  • cabazitaxel
  • sipuleucel-T